Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer

References

• Farin K, Dores GAM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–2150. doi:10.1200/JCO.2005.05.230816682732
   PubMed Web of Science ®Google Scholar
• Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230(4730):1132–1139.2999974
   PubMed Web of Science ®Google Scholar
• Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. J Sci. 1986;232(4758):1644–1646. doi:10.1126/science.3012781
   PubMed Web of Science ®Google Scholar
• Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER-2/neu expression: a major prognostic factor in endometrial cancer. J Gynecologic Oncol. 1992;45(1):86–87. doi:10.1016/0090-8258(92)90539-U
   Google Scholar
• Kaptain S, Tan LK, Chen BJ. Her-2/neu and breast cancer. Diagn Mol Pathol. 2001;10(3):139–152.11552716
   PubMedGoogle Scholar
• Eltze E, WãLfing C, Von SD, Piechota H, Buerger H, Hertle L. Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol 2005;26(6):1525–1531.
   Google Scholar
• Schuell B, Gruenberger T, Scheithauer W, Zielinski C, Wrba F. HER 2/neu protein expression in colorectal cancer. BMC Cancer. 2006;6(1):123.
   Google Scholar
• Reichelt U, Duesedau P, Mch T, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20(1):120.
   Google Scholar
• Fujita TJLO. Targeted therapy for gastric cancer. The Lancet Oncology 2012;13(3):377–389.
   Google Scholar
• Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes–a systematic review. Int J Cancer. 2012;130(12):2845–2856. doi:10.1002/ijc.2629221780108
   PubMed Web of Science ®Google Scholar
• Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2010;52(7):797–805.
   Google Scholar
• Marx AH, Simon R, Sauter GJHP. HER-2 amplification is highly homogenous in gastric cancer—reply. Hum Pathol 2010;41(2):305–306.
   Google Scholar
• Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MPJH. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011;59(5):832–840. doi:10.1111/j.1365-2559.2011.04017.x22092394
   PubMed Web of Science ®Google Scholar
• Baykara M, Benekli M, Ekinci O, et al. Clinical significance of HER2 overexpression in gastric and gastroesophageal junction cancers. Journal of Gastrointestinal Surgery. 2015;19(9):1–7.
   Google Scholar
• Montes HZ. TNM classification of malignant tumors, 7th edition. International Journal of Radiation Oncology Biology Physics. 2010;78(4):1278. doi:10.1016/j.saa.2010.12.077
   Google Scholar
• Borchard FJH. Classification of gastric carcinoma. Hepato-Gastroenterology. 1990;37(2):223–232.2187787
   PubMedGoogle Scholar
• Bang YJ, Van CE, Feyereislova AJL. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junc tion cancer(ToGA): aphase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X20728210
   PubMed Web of Science ®Google Scholar
• Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637–650. doi:10.1038/modpathol.2011.19822222640
   PubMed Web of Science ®Google Scholar
• Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol. 2008;43(4):256–264. doi:10.1007/s00535-008-2177-618458840
   PubMed Web of Science ®Google Scholar
• Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature. J Cancer. 2012;3(1):137–144. doi:10.7150/jca.409022481979
   PubMed Web of Science ®Google Scholar
• Dong IP, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51(8):1371–1379. doi:10.1007/s10620-005-9057-116868827
   PubMed Web of Science ®Google Scholar
• Shuyi W, Gang Z, Liangdong C, Bin XJ. Effect of HER-2/neu over-expression on prognosis in gastric cancer: a meta-analysis. Asian Pacific Journal of Cancer Prevention. 2011;12(6):1417–1423.
   Google Scholar
• Gorana G, Janez L, Juan Antonio C, et al. HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the coressponding whole-tissue sections with a supplemental fish study. Pathology & Oncology Research. 2013;19(4):855–865.
   Google Scholar
• Gravalos C, Jimeno AJ. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–1529. doi:10.1093/annonc/mdn16918441328
   PubMed Web of Science ®Google Scholar
• Aizawa M, Nagatsuma AK, Kitada K, et al. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17(1):34.
   Google Scholar
• Yung-Jue B, Eric VC, Andrea F, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X20728210
   PubMed Web of Science ®Google Scholar